Ivan Che­ung's post-Ei­sai life takes hold at Next­Point Ther­a­peu­tics; Sanofi, Take­da an­nounce CFO ex­its

Ivan Che­ung, who led Ei­sai’s US busi­ness and was a cen­tral fig­ure in the biotech’s Alzheimer’s work, has stepped in­to the CEO po­si­tion at a Cam­bridge, MA start­up.

He start­ed run­ning im­muno-on­col­o­gy out­fit Next­Point Ther­a­peu­tics last month, hav­ing de­part­ed Ei­sai short­ly af­ter Ei­sai se­cured full FDA ap­proval for its Alzheimer’s treat­ment Leqem­bi last sum­mer. The 30-em­ploy­ee up­start has reeled in back­ing from Big Phar­mas like Sanofi and Bay­er, as well as VC firms like MPM Cap­i­tal and Catalio Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER